CR6706A - Pirido (2,3-d) pirimidin-2-7-diaminas inhibidores de cinasas - Google Patents

Pirido (2,3-d) pirimidin-2-7-diaminas inhibidores de cinasas

Info

Publication number
CR6706A
CR6706A CR6706A CR6706A CR6706A CR 6706 A CR6706 A CR 6706A CR 6706 A CR6706 A CR 6706A CR 6706 A CR6706 A CR 6706A CR 6706 A CR6706 A CR 6706A
Authority
CR
Costa Rica
Prior art keywords
compounds
substituted
unsubstituted
pirido
diamins
Prior art date
Application number
CR6706A
Other languages
English (en)
Inventor
Myra Dobrusin Ellen
Prasad Venkata Nagendra Josyula Vara
John Booth Richard
Joseph Mcnamara Dennis
Laurence Toogood Peter
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of CR6706A publication Critical patent/CR6706A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Consiste en compuestos de formula en la cual R2, R7, R13, y R15, son independientemente, hidrogeno o alquilo inferior sustituido o sin sustituir, alquenilo inferior sustituido o sin sustituir, alquinilo inferior sustituido o sin sustituir, o bien -(CH2) nR112 sustituido o sin sustituir y otros compuestos. Estos compuestos y sus composiciones farmaceuticas son utiles para tratar trastornos proliferativos celulares, tales como cancer y restenosis. Estos compuestos son potentes inhibidores de cdks y de cinasas mediadas por factor de crecimiento.
CR6706A 2000-01-25 2002-07-17 Pirido (2,3-d) pirimidin-2-7-diaminas inhibidores de cinasas CR6706A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17826100P 2000-01-25 2000-01-25

Publications (1)

Publication Number Publication Date
CR6706A true CR6706A (es) 2005-04-04

Family

ID=22651853

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6706A CR6706A (es) 2000-01-25 2002-07-17 Pirido (2,3-d) pirimidin-2-7-diaminas inhibidores de cinasas

Country Status (34)

Country Link
EP (1) EP1254137A1 (es)
JP (1) JP4047010B2 (es)
KR (1) KR20020065939A (es)
CN (1) CN1395578A (es)
AP (1) AP2002002586A0 (es)
AR (1) AR030044A1 (es)
AU (1) AU2542501A (es)
BG (1) BG106850A (es)
BR (1) BR0107751A (es)
CA (1) CA2397961C (es)
CO (1) CO5261549A1 (es)
CR (1) CR6706A (es)
CZ (1) CZ20022475A3 (es)
DZ (1) DZ3266A1 (es)
EA (1) EA200200643A1 (es)
EE (1) EE200200405A (es)
GT (1) GT200100016A (es)
HN (1) HN2001000013A (es)
HU (1) HUP0204141A3 (es)
IL (1) IL150545A0 (es)
IS (1) IS6443A (es)
MA (1) MA26868A1 (es)
MX (1) MXPA02007221A (es)
NO (1) NO20023527L (es)
OA (1) OA12161A (es)
PA (1) PA8510701A1 (es)
PE (1) PE20011066A1 (es)
PL (1) PL356802A1 (es)
SK (1) SK10632002A3 (es)
SV (1) SV2002000294A (es)
TN (1) TNSN01014A1 (es)
WO (1) WO2001055147A1 (es)
YU (1) YU50402A (es)
ZA (1) ZA200205879B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
EP2404603A1 (en) 2000-10-23 2012-01-11 Glaxosmithkline LLC Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
MXPA04010267A (es) 2002-04-19 2005-02-03 Smithkline Beecham Corp Compuestos novedosos.
KR20050084027A (ko) * 2002-11-28 2005-08-26 쉐링 악티엔게젤샤프트 Ｃｈｋ-, ｐｄｋ- 및 ａｋｔ-억제성 피리미딘, 그의제조방법 및 약제로서의 그의 용도
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
TW200502236A (en) * 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
US7550589B2 (en) * 2004-09-21 2009-06-23 Hoffman-La Roche Inc. 6-(2-alkyl-phenyl)-pyrido[2,3-D]pyrimidines useful as protein kinase inhibitors
PE20061351A1 (es) 2005-03-25 2007-01-14 Glaxo Group Ltd COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38
US20090137550A1 (en) 2005-03-25 2009-05-28 Glaxo Group Limited Novel Compounds
TW200724142A (en) 2005-03-25 2007-07-01 Glaxo Group Ltd Novel compounds
EP1865959A2 (en) 2005-03-25 2007-12-19 Glaxo Group Limited Process for preparing pyridoý2,3-d¨pyrimidin-7-one and 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one derivatives
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
WO2007009911A1 (en) * 2005-07-21 2007-01-25 F. Hoffmann-La Roche Ag PYRIDO [2 , 3-D] PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS
AU2006279992A1 (en) 2005-08-09 2007-02-22 Irm Llc Compounds and compositions as protein kinase inhibitors
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
FR2910813B1 (fr) * 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
EA201100879A1 (ru) * 2008-12-01 2012-01-30 Мерк Патент Гмбх Производные пиридопиримидина в качестве ингибиторов аутотаксина
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
EP3733184B1 (en) * 2013-03-14 2023-08-30 Icahn School of Medicine at Mount Sinai Pyrimidine compounds for use in the treatment of cancer
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
KR101671404B1 (ko) * 2014-09-02 2016-11-02 한국원자력의학원 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도
CN107286180B (zh) * 2016-04-11 2019-07-02 上海勋和医药科技有限公司 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
MX9702245A (es) * 1994-11-14 1997-06-28 Warner Lambert Co Seis-aril-pirido(2,3-d)pirimidinas y naftiridinas para inhibir la proliferacion celular mediada por la proteina cinasa tirosina.
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
EE200000706A (et) * 1998-05-26 2002-06-17 Warner-Lambert Company Bitsüklilised pürimidiinid ja bitsüklilised 3,4-dihüdropürimidiinid kui rakkude proliferatsiooni inhibiitorid

Also Published As

Publication number Publication date
TNSN01014A1 (fr) 2005-11-10
NO20023527L (no) 2002-09-10
PL356802A1 (en) 2004-07-12
CZ20022475A3 (cs) 2003-03-12
AP2002002586A0 (en) 2002-09-30
JP2003523357A (ja) 2003-08-05
WO2001055147A1 (en) 2001-08-02
EA200200643A1 (ru) 2002-12-26
CN1395578A (zh) 2003-02-05
EP1254137A1 (en) 2002-11-06
CA2397961C (en) 2008-08-26
YU50402A (sh) 2005-11-28
MA26868A1 (fr) 2004-12-20
CA2397961A1 (en) 2001-08-02
NO20023527D0 (no) 2002-07-24
OA12161A (en) 2006-05-08
KR20020065939A (ko) 2002-08-14
BG106850A (bg) 2003-02-28
CO5261549A1 (es) 2003-03-31
DZ3266A1 (fr) 2001-08-02
HUP0204141A2 (hu) 2003-04-28
GT200100016A (es) 2001-10-19
AU2542501A (en) 2001-08-07
IL150545A0 (en) 2003-02-12
BR0107751A (pt) 2002-11-12
IS6443A (is) 2002-06-25
HUP0204141A3 (en) 2005-03-29
SV2002000294A (es) 2002-07-16
SK10632002A3 (sk) 2003-06-03
HN2001000013A (es) 2001-06-18
AR030044A1 (es) 2003-08-13
ZA200205879B (en) 2003-09-29
PA8510701A1 (es) 2002-12-11
MXPA02007221A (es) 2002-11-29
EE200200405A (et) 2003-12-15
PE20011066A1 (es) 2001-10-22
JP4047010B2 (ja) 2008-02-13

Similar Documents

Publication Publication Date Title
AR030044A1 (es) Pirido (2,3-d ) pirimidin-2,7-diaminas inhibidores de quinasas
CR6736A (es) 5-alquilpirido[2,3-d[ piridinas como inhibidores de tirosina kinasa
BRPI0507644A (pt) pirazolopirimidinas como inibidores de cinase dependente de ciclina
ES2192877T3 (es) 4-alquenil (y alquinil) oxindoles como inhibidores de kinasas ciclina-dependientes, en particular cdk2.
DK1648905T3 (da) Inhibitorer for thienopyridin- og furopyridinkinase
CR7899A (es) Compuestos de triciclicos inhbidores de proteina quinasa para mejorar la eficacia de agentes antienoplasticos y derivados de diazenpamdionilo como inhibidores de quinasa
PE20090058A1 (es) Compuestos carboxamida heterociclicos como inhibidores de la actividad akt
TW200407311A (en) N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders
GEP20125658B (en) Imidazotriazines and imidazo pyrimidines as kinase inhibitors
TW200510380A (en) Mitotic kinesin inhibitors
YU61402A (sh) Pirol substituisani 2 indolinon protein kinazni inhibitori
ECSP078062A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
GEP20125368B (en) Kinase inhibitors
MXPA05011296A (es) Conjugados de fosfonato inhibidores de la cinasa.
BRPI0511975A (pt) pirazolopirimidinas
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
TN2009000329A1 (fr) DERIVES DE 2-AMINO-5,7-DIHYDRO-6H-PYRROLO[3,4-d]-PYRIMIDINE SERVANT D'INHBITEURS DE HSP-90 POUR LE TRAITEMENT DU CANCER
BRPI0606463A2 (pt) derivados triazol substituìdos com antagonistas de oxitocina
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
CR9579A (es) Inhibidores de tirosina quinasa
PA8613001A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina
AR026037A1 (es) Indolinonas sustituidas en posicion 5, su preparacion y su utilizacion como medicamentos
AR056860A1 (es) Derivados de triazol inhibidores de receptores de quinasa tgf-beta1, composiciones farmaceuticas que los contienen y usos para el tratamiento de tumores
ES2192878T3 (es) 4,5-azolo-oxindoles.
AU3324201A (en) Tosylproline analogs as thymidylate synthase inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)